Special Feature

User Panel

My Panel

My Panel

Bookmark Science Articles

Recent News
Bookmark / Share This Science Site

Preliminary results of interstitial motexafin lutetium-mediated PDT for prostate cancer.

Preliminary results of interstitial motexafin lutetium-mediated PDT for prostate cancer. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

  • Abstract Text of This Paper
  • Journal Published
  • MeSH Keywords of This Abstract
  • Chemicals and Substances Used in this Paper
  • Grants and Granting Agency of this Research
  • Database Accession Numbers Used in this Paper
  • Related Papers
  • Related Research Tags
  • Rate this Research Paper
  • Preliminary results of interstitial motexafin lutetium-mediated PDT for prostate cancer. Abstract Text:

    k l duK L Du,r mickR Mick,t m buschT M Busch,t c zhuT C Zhu,j c finlayJ C Finlay,g yuG Yu,a g yodhA G Yodh,s b malkowiczS B Malkowicz,d smithD Smith,r whittingtonR Whittington,d strippD Stripp,s m hahnS M Hahn,

    BACKGROUND AND OBJECTIVES: Interstitial photodynamic therapy (PDT) is an emerging modality for the treatment of solid organ disease. Our group at the University of Pennsylvania has performed extensive studies that demonstrate the feasibility of interstitial PDT for prostate cancer. Our preclinical and clinical experience is herein detailed. STUDY DESIGN/MATERIALS AND METHODS: We have treated 16 canines in preclinical studies, and 16 human subjects in a Phase I study, using motexafin lutetium-mediated PDT for recurrent prostate adenocarcinoma. Dosimetry of light fluence, drug level and oxygen distribution for these patients were performed. RESULTS: We demonstrate the safe and comprehensive treatment of the prostate using PDT. However, there is significant variability in the dose distribution and the subsequent tissue necrosis throughout the prostate. CONCLUSIONS: PDT is an attractive option for the treatment of prostate adenocarcinoma. However, the observed variation in PDT dose distribution translates into uncertain therapeutic reproducibility. Our future focus will be on the development of an integrated system that is able to both detect and compensate for dose variations in real-time, in order to deliver a consistent overall PDT dose distribution.

    Preliminary results of interstitial motexafin lutetium-mediated PDT for prostate cancer. Publishing Authors By Initials

    kl duKL Du,r mickR Mick,tm buschTM Busch,tc zhuTC Zhu,jc finlayJC Finlay,g yuG Yu,ag yodhAG Yodh,sb malkowiczSB Malkowicz,d smithD Smith,r whittingtonR Whittington,d strippD Stripp,sm hahnSM Hahn,

    For similar circulatory and respiratory physiology: cardiovascular physiology: cardiovascular physiologic processes: blood circulation: regional blood flow research abstracts see: circulatory and respiratory physiology: cardiovascular physiology: cardiovascular physiologic processes: blood circulation: regional blood flow research

    PUBMED ID PMID:

    MEDLINE DATE:

    Preliminary results of interstitial motexafin lutetium-mediated PDT for prostate cancer. Journal Published:

    PUBLICATION TYPE: Research Support, N.I.H., Extr

    Journal: Lasers in surgery and medicine

    VOLUME: 38

    Page Numbers: 427-34

    Journal Abbreviation:

    ISSN: 0196-8092

    DAY: 3

    MONTH: Jun

    YEAR: 2006

    Preliminary results of interstitial motexafin lutetium-mediated PDT for prostate cancer. Information

    Number of References:

    LANGUAGE: eng

    NlmUniqueID: 8007168

    Preliminary results of interstitial motexafin lutetium-mediated PDT for prostate cancer. Keywords Mesh Terms:

    KEYWORDS: Regional Blood Flow

    MESH TERMS: drug effects

    Chemical & Substance for Abstract: Preliminary results of interstitial motexafin lutetium-mediated PDT for prostate cancer. Information

    Substance Name: Oxygen

    Registry Number: 7782-44-7

    Grant and Affiliation Information for Preliminary results of interstitial motexafin lutetium-mediated PDT for prostate cancer.

    AFFILIATION: Department of Radiation Oncology, Hospital of the University of Pennsylvania, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA.

    Country: United States

    United States Research PublicationUnited States Research Publication

    AGENCY: United States NCI

    GRANT: R21 CA88064

    ACRONYM: CA

    MEDLINETA: Lasers Surg Med

    REFSOURCE:

    DATABASENAME:

    ACCESSION NUMBER:

    Number Hits: 0

    Preliminary results of interstitial motexafin lutetium-mediated PDT for prostate cancer Related Publications

     

    Molecular Station USER Menu

    Welcome to Molecular Station!

    You have to register before you can post on our forums or use our advanced features. Register Now! Its Free and Fast!

    Already registered? Login now below.

    User Name:

    Password:

    Already registered and Forgot your password? Click below to recover it.

    Recover Lost Password

    Join now - it's fast and free!

    Molecular Station is THE largest network of researchers, scientists and science lovers anywhere!

    Research Terms of Usage and Disclaimer
    Home
    Features

    Protocols

    DNA Forum

    Science Forum

    DNA Forum
    Biology Forum

    Science News


    [CaRP] XML error: Invalid document end at line 2

    For more click here:Science News